Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 29 October 2026.

Announcements

6,258

Total raised

£165B

disclosed amounts

This month

£523M

raised so far

Series A
£5.0M

The oversubscribed funding round was led by AV8 Ventures to support the company's market launch.

"The UK mortgage market is one of the very few sectors in which consumers are yet to seriously benefit from advances in technology. We have built a technology platform that will lead to better outcomes across the eco-system, in particular for borrowers and mortgage intermediaries. M:QUBE has the power to transform this largely un-innovated market for the benefit of all key stakeholders and improve returns for banks, building societies and institutional investors in the process."
— Stuart Cheetham, Co-founder and CEO
Pre-Seed
£1.0M

The pre-seed round was led by Collab+Sesame with participation from Techstars London.

"I was a huge fan of Sesame Street as a child, and couldn't imagine a more perfect lead investor than Collab+Sesame, who share our values of kindness, communication, learning through play, and humour. We're looking forward to working closely with Sesame Workshop to help us develop Banjo Robinson into an even more valuable experience for children and families."
— Kate Boyle, CEO and founder
Series B
£31.1M

The funding round was led by Summit Partners with participation from Goldman Sachs to support North American expansion.

"Gaps in cybersecurity knowledge meaningfully increase risk to an organization, creating vulnerability and presenting opportunity for attackers. The rapid, constantly evolving threat landscape has made traditional classroom training for cyber skills obsolete,"
— James Hadley, CEO and Founder
Series A
£2.2M

The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.

"This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes."
— Paul Finn, CEO